Epigenomic analysis in breast cancer cells with DOT1L inhibition
DOT1L, a histone H3 lysine 79 (H3K79) methyltransferase, is a potential therapeutic target in various malignancies. In the current study, we aimed to clarify the antitumor effect of DOT1L inhibition in breast cancer. Estrogen receptor (ER)-positive/HER2-negative breast cancer cells (MCF7) and ER-negative/HER2-positive cells (SKBR3) were treated with DOT1L inhibitors (SGC0942, EPZ-5676) for 6 or 9 days. Chromatin immunoprecipitation (ChIP) was performed as using rabbit anti-trimethyl H3K4 Ab (#04-745, Sigma-Aldrich, St. Louis, MO, USA).